Tag:
Sanofi-Aventis
Latest Headlines
Latest Headlines
Japan OKs Sanofi's inactivated polio vaccine
Japan has granted marketing approval for its first inactivated polio vaccine (IPV), Sanofi's Imovax Polio, and will begin using the vaccine in public immunization programs beginning Sept. 1.
Sanofi, BMS collect their $444M in Plavix damages
Apotex has finally paid its Plavix dues. The generics maker has handed over $444 million to Sanofi ( $SNY ) and Bristol-Myers Squibb ( $BMY ), as repayment for its premature launch of generic Plavix back...
Sanofi CEO: Look out below, profits are falling
It wasn't Sanofi's fourth-quarter profits, which grew by 13%. Nor was it the 8.8% increase in sales for the period, or the 5.3% increase in 2011 sales, to €33.39 billion ($44.3...
Is Sanofi destined to be 'small player' in MS?
Sanofi ( $SNY ) CEO Chris Viehbacher ( photo ) is talking up trial results on his multiple sclerosis hopeful Lemtrada, acquired in his buyout of Genzyme . But advances by other companies are making it
Sanofi, Novartis favor diagnostics partnerships over M&A
The initial speculation--or was it a wish?--that a Sanofi ( $SNY ) or Novartis ( $NVS ) might mount a counterbid to Roche's hostile $5.7 billion offer for Illumina was chilled rather effectively by a
Europe makes Sanofi chief thankful for emerging markets
Although Sanofi ( $SNY ) CEO Christopher Viehbacher ( photo ) sees a glimmer of light at the end of the long Eurozone tunnel, he's still glad the French drugmaker doesn't depend on Europe as much as it
Genzyme plant approval marks GMP comeback
The Genzyme unit of Sanofi ( $SNY ) announced today that it has won FDA approval for its new Framingham, MA, facility, the new production home of Fabry disease drug Fabrazyme. The plant won European ...
Genzyme wins key FDA approval for new plant
You can bet that Sanofi's ( $SNY ) top brass are celebrating this evening. The French drugmaker's Genzyme unit won the long-sought FDA approval for its new plant in Framingham, MA. That facility can
Genzyme revives Fabrazyme with EMA plant OK
Genzyme flexed some market muscle Wednesday when it announced the European Medicines Agency's approval of a new U.S. facility for production of Fabrazyme . Perhaps most immediately affected by the...
NICE nixes Sanofi's Jevtana on cost, side effects
The U.K.'s cost-effectiveness watchdog has officially snubbed the Sanofi ( $SNY ) prostate cancer treatment Jevtana. The National Institute for Health and Clinical Excellence won't recommend the drug
